📌 Key Takeaways
- The FDA approved RADIESSE® (calcium hydroxylapatite / CaHA) for décolleté wrinkle treatment on March 31, 2026.
Merz Aesthetics made the official announcement on April 8, 2026. - This is RADIESSE’s 4th FDA-cleared indication — following facial wrinkles, hand volume, and jawline contouring.
Indicated for patients aged 22 and older; diluted 1:2 with saline. - Merz positions RADIESSE as “the first and only regenerative biostimulator approved in the U.S. for both face and body.”
Note: this is Merz’s own classification — the FDA has not officially defined the “biostimulator” category. - Safety data for the décolleté indication does not extend beyond 84 weeks (per Instructions for Use, 2026).
Satisfaction figures cited by Merz are internal company data and have not been independently peer-reviewed.
For years, aesthetic medicine has treated the face as its primary canvas.
That assumption is quietly shifting.
On March 31, 2026, the U.S. Food and Drug Administration approved a new indication for RADIESSE® —
the calcium hydroxylapatite (CaHA) injectable —
specifically for the treatment of wrinkles in the décolleté area.
Merz Aesthetics formally announced the clearance on April 8, 2026.
The approval marks RADIESSE’s fourth FDA-cleared indication,
following facial wrinkles (2006), hand volume restoration, and jawline contouring.
Merz now describes the product as “the first and only regenerative biostimulator approved in the U.S. for both face and body.”
That framing is Merz’s own — the FDA does not formally recognize “biostimulator” as a regulatory category.
RADIESSE® is an injectable composed of CaHA microspheres suspended in a carboxymethylcellulose (CMC) gel carrier.
It is classified by Merz and supporting scientific literature as a biostimulator — a product that stimulates collagen and elastin production rather than simply filling volume.
Biostimulator refers broadly to injectables that trigger tissue regeneration post-injection,
as distinct from hyaluronic acid (HA) fillers, which primarily add volume.
Décolleté describes the neck-to-chest area (around the clavicle),
a zone prone to visible aging and increasingly targeted in non-surgical body aesthetics.
From “Fill” to “Stimulate”: What Makes RADIESSE Different
RADIESSE was first cleared by the FDA in 2006 for facial wrinkle correction.
Its mechanism differs from conventional HA fillers in a clinically meaningful way.
Where HA fillers physically add volume to soft tissue,
biostimulators like RADIESSE are designed to trigger the body’s own regenerative response.
RADIESSE’s CaHA microspheres are believed to stimulate fibroblasts,
promoting collagen and elastin synthesis over time
(per Merz communications and supporting scientific literature;
note: this mechanism has not been established through large-scale randomized controlled trials).
The result, in theory, is a longer-lasting effect than HA fillers —
not by adding material from outside, but by prompting structural change from within.
The 4th Indication: What the FDA Actually Approved
Merz has cited figures including:
“80%+ of patients satisfied with skin tightening,”
“83% willing to repeat treatment at 1 year,” and
“90% of providers observed improvement at 4 months.”
All of these figures are sourced as “Data on file, Merz North America, Inc.” —
meaning they are internal company data.
Study design, control groups, and bias assessments have not been publicly disclosed.
These numbers may reflect a genuine positive trend,
but they should not be treated as equivalent to independently peer-reviewed research.
The Body Aesthetics Shift: Why “Face and Beyond” Is Gaining Ground
A pattern is emerging among patients who have undergone facial aesthetic treatments:
“My face looks refreshed — but my décolleté gives away my age.”
This observation is driving demand for non-surgical body treatments at a measurable pace.
“Body aesthetics” — the use of injectables and energy-based devices on areas beyond the face
(décolleté, hands, neck, abdomen) — has expanded significantly over the past several years.
RADIESSE is not alone in this space:
PCL (polycaprolactone) threads, PDO threads, and monopolar radiofrequency devices
are all seeing increased adoption for non-surgical body contouring and skin tightening.
Three structural forces are driving the “face to body” shift in aesthetic medicine:
① The “treated face, aging body” paradox.
Patients who have optimized their facial appearance increasingly notice contrast with untreated areas — décolleté, hands, and neck.
② Demographic aging + broader exposure awareness.
As populations age, the desire to address visible aging across all exposed skin — not just the face — is growing.
③ The biostimulator concept expanding the treatment map.
As clinicians and patients become familiar with regenerative injectables,
the question “can we use this elsewhere?” naturally follows.
The 2026 FDA approval gives regulatory weight to what was already a clinical trend.
(NERO Editorial Analysis)
For anyone who has wondered, “My décolleté bothers me — but I don’t know where to start,”
this approval creates a concrete conversation to have with a provider.
Lowering the information barrier around body aesthetics is itself meaningful progress.
That said: FDA clearance in the U.S. does not automatically translate to approved use elsewhere.
Regulatory status varies by country — always verify local approval before pursuing any treatment.
From a clinic strategy perspective,
“body aesthetics” is one of the fastest-growing categories in aesthetic medicine —
and the trajectory will likely accelerate over the next several years.
The RADIESSE décolleté approval represents a meaningful first step
in building the evidence base for CaHA use beyond the face.
For providers considering offering this treatment,
verifying local regulatory status and designing clear patient education
should come before anything else.
(NERO Editorial Analysis)
Summary
- The FDA approved RADIESSE® for décolleté wrinkle treatment on March 31, 2026.
Merz Aesthetics announced the approval on April 8, 2026.
Indicated for patients 22 and older; diluted 1:2 with saline.
This is RADIESSE’s 4th FDA-cleared indication (face / hands / jawline / décolleté). - Safety data for the décolleté indication does not extend beyond 84 weeks (~20 months)
per the 2026 Instructions for Use.
All satisfaction figures cited by Merz are internal company data (“Data on file”)
and have not been independently peer-reviewed. - This is a U.S. FDA approval only.
It does not automatically confer approved status in other countries.
Regulatory clearance and approved indications for CaHA products vary by jurisdiction
and must be verified locally before clinical use. - The approval formalizes a broader industry trend:
non-surgical body aesthetics is expanding beyond the face,
and biostimulators are at the center of that shift.
Evidence accumulation and local regulatory compliance remain essential
for responsible adoption. (NERO Editorial Analysis)
the treatment of wrinkles in the décolleté area.
This is the product’s 4th FDA-cleared indication, following facial wrinkles (2006),
hand volume restoration, and jawline contouring.
The approved protocol requires dilution 1:2 with saline and is indicated for patients aged 22 and older.
rather than simply adding volume to soft tissue.
RADIESSE’s CaHA microspheres are believed to activate fibroblasts post-injection,
promoting structural tissue regeneration over time.
Hyaluronic acid (HA) fillers, by contrast, primarily work by physically filling space.
Note: “biostimulator” is Merz’s classification — it is not an official FDA regulatory category.
It does not automatically grant approved status in other countries.
Regulatory clearance, approved indications, and permitted injection sites for CaHA products
vary by country and must be confirmed through local regulatory authorities
before any clinical application.
Sources:
1. Merz Aesthetics. “Merz Aesthetics Receives FDA Approval for RADIESSE® for the Treatment of Wrinkles in the Décolleté Area.” April 8, 2026. merzaesthetics.com (Primary source, directly verified)
2. RADIESSE® Instructions for Use. 2026. (Décolleté indication safety data — via Merz official documentation)
